View ALL

"Beyond Advair" drug reaches next phase of clinical trials

Drugmaker Theravance has announced that its part of the Beyond Advair Collaboration with GlaxoSmithKline (GSK) has reached the next phase of clinical trials. Theravance's compound, 642444, is being tested to be part of a combination drug with GSK's compound, 159797. The goal of the project is to develop a once-a-day inhaled medication to treat mild to moderate asthma.

(Market Wire) UPDATED 06/12/2006
Click here to read the full story

Conditions: | asthma - 259 Articles

Helpful?

Navigation

Member Picks

Three vitamin supplements reflux sufferers may need
View Full Story

Chronic pain harms the brain
View Full Story

Research your meds on the Treatments tab
View Full Story

Caffeine could spell trouble for diabetics
View Full Story

MedTrackAlert is a consumer health information company dedicated to helping people better understand the benefits and risks of prescription medications. We provide our members with important, time-sensitive news to keep them aware of new advances, adverse drug interactions, and potential dangers related to the medications they take. With trusted prescription news and condition coverage we can help you maintain collaboration with your doctors in the management of your health. More About Us.

Copyright © 2008 The HealthCentral Network, Inc. All rights reserved. All brands listed are the trademarks of their respective owners and are not trademarks of The HealthCentral Network, Inc. 1655 Fort Myer Drive, Suite 400, Arlington, Virginia 22209.

Disclaimer: The information provided is not intended to be medical advice. You should contact your physician about your medication and health care. HealthCentral Network, Inc. is not responsible for content provided by third-party Web sites. We will always respect your privacy.

Advertise with Us
Email Policy